Enteroccocus faecalis empyema and off-label use: case report A 34-year-old man developed Enteroccocus faecalis empyema during off-label treatment with tocilizumab for COVID-19 *. Additionally, he received off-label treatment with hydroxychloroquine, azithromycin and ceftriaxone for COVID-19. The man was admitted due to dyspnoea and fever. He was eventually diagnosed with COVID-19. On day 2 of hospitalisation, he was intubated due to acute hypoxaemic respiratory failure. He started receiving off-label treatment with hydroxychloroquine, ceftriaxone and azithromycin [dosages and routes not stated]. Laboratory investigations revealed IL-6 level 46 pg/mL, CRP 217.61 mg/L, ferritin 15424 ng/mL and estimated sedimentation rate 68 mm/hour. He received tocilizumab 400mg on day 2 and on day 23 [routes not stated] as an off-label treatment for COVID-19. However, his condition continued to deteriorate (PaO2/FiO2 ratio 0.76). On day 9, veno-venous ECMO was initiated. On day 14, a chest X-ray revealed right-sided pleural effusion, which was drained using a chest tube. Culture showed Enterococcus faecalis. He was thus diagnosed with Enteroccocus faecalis empyema. The immunosuppressants therapy with tocilizumab was considered as a risk factor for the Enteroccocus faecalis empyema [time to reaction onset not stated]. The man was treated with vancomycin. His condition improved gradually. On day 34, ECMO was discontinued. Subsequently, the tracheostomy tube was removed and he was discharged on day 42.